SOURCE: Duravest, Inc.

June 23, 2006 00:45 ET

Duravest and PST Receive Strong Response at EULAR 2006

Doctors and Experts Worldwide Provide Outstanding Reviews at Annual European Congress of Rheumatology

CHICAGO, IL and MUNICH, GERMANY -- (MARKET WIRE) -- June 23, 2006 -- Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV), and its subsidiary company, PST, GmbH, has participated in the 7th Annual EULAR Congress this week with wide-ranging acceptance and very positive reviews of PST's "Pulse Signal Therapy" products.

EULAR, or The European League Against Rheumatism, hosts its annual conference covering the broad spectrum of the rheumatic diseases, including basic science and clinical symposia, abstract sessions, case studies, workshops, special interest group sessions and state-of-the-art lectures. PST was an exhibitor at the conference.

"We are extremely pleased with the feedback we received at EULAR from some the world's leading rheumatologists," Mr. Michael Bencak, PST's Director of Marketing noted. "With the further internationalization of our distribution network, we have already initiated our plan to aggressively target new markets over the coming months."

PST received very strong interest from physicians from several countries participating at EULAR 2006, including Paraguay, Saudi Arabia, India, Czech Republic, Poland, and South Korea.

PST has developed a safe, non-invasive and patented pulsed electromagnetic signal technology that stimulates the healing of connective tissue injuries. The company generally treats those who suffer from osteoarthritis as well other orthopedic and sports-related injuries. Osteoarthritis affects approximately 19% of the U.S. population, or 33.4 million Americans, and there are 7.7 million sports related injuries per year in the United States alone. To date, more than 300,000 patients have been treated with PST's patented technology.

"Duravest is very excited about the continuing success of PST's products and looks forward to further achievements as we enter new markets," said Dr. Ogan Gurel, CEO of Duravest, Inc., and interim CEO of PST.

About Duravest, Inc.

Duravest, Inc. (PINKSHEETS: DUVT) (XETRA: DUV) is a publicly traded holding company that initiates and develops strategic investments in next-generation convergent medical technologies. Duravest currently has two subsidiaries: Estracure, Inc. -- based in Montreal, Canada -- which is developing a next-generation coronary stent based on proprietary 17-beta-estradiol and PST, GmbH -- based in Munich, Germany which currently markets patented bio-magnetic therapies for orthopedic conditions and their associated pain management. Estracure is developing a next-generation stent that specifically addresses potential safety issues with the current generation of coronary drug-eluting stents and thus represents not just a potential niche player but a replacement product in the market. The active agent in the Estracure stent -- 17-beta-estradiol -- has a pro-healing effect (by stimulating re-endothelization) that has been documented by extensive in vitro and in vivo studies. The Duravest strategy encompasses three themes: (1) rapid commercialization of next-generation medical technologies by providing its portfolio of subsidiaries with financial, operational and scientific support, (2) prioritization of safety and (3) development of convergent medical technologies that span the traditional categories of biotechnology, pharmaceuticals, healthcare IT and medical devices.

Safe Harbor Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals or assumptions of future events are not statements of historical fact and may be considered forward looking statements. They involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated.

Contact Information